MktsMarkets

Spero Therapeutics, Inc.
NASDAQ: SPROKey statistics
SPRO News
Stories mentioning SPRO from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 12,574 | 0.00 | 0.00 | 12.00 | 52.00 | 65.00 | 114.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 2,909 | 5,592 | 8,597 | 10,672 | 13,606 | 28,836 | 26,864 | 23,725 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 7,796 | 9,892 | 13,358 | 16,633 | 20,605 | 36,769 | 32,062 | 29,258 |
| Operating Income (Loss) | (7,538) | 31,405 | (7,916) | (2,444) | (14,731) | (21,725) | (18,593) | (19,061) |
| Interest Income | 336.00 | 376.00 | 532.00 | 740.00 | 864.00 | 1,028 | 1,182 | 1,198 |
| Interest Expense | ||||||||
| Other Expense | (1.00) | 0.00 | 2.00 | 4.00 | 1.00 | 99.00 | (26.00) | 1.00 |
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 290.00 | ||||||
| Net Income (Loss) | (7,203) | 31,520 | (7,382) | (1,700) | (13,866) | (20,888) | (17,147) | (17,862) |
| Earnings Per Share (Basic) | (0.13) | 0.56 | (0.13) | (0.03) | (0.25) | (0.39) | (0.32) | (0.33) |
| Earnings Per Share (Diluted) | (0.13) | 0.53 | (0.13) | (0.03) | (0.25) | (0.39) | (0.32) | (0.33) |
| Weighted Average Shares Outstanding (Basic) | 57,282 | 56,020 | 56,281 | 56,027 | 55,376 | 54,038 | 54,125 | 53,958 |
| Weighted Average Shares Outstanding (Diluted) | 57,282 | 59,039 | 56,281 | 56,027 | 55,376 | 54,038 | 54,125 | 53,958 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About SPRO
Spero Therapeutics, Inc. (NASDAQ: SPRO) is a stock listed on the Nasdaq Stock Market under the ticker symbol SPRO. It last traded at $1.06 (Oct 30, 2026, 4:00 PM ET), down 4.5% on the day. That gives Spero Therapeutics a market capitalisation of $62.3M and a price-to-earnings ratio of 8.4.
Over the past 52 weeks SPRO has traded between $1.04 and $3.08.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $7.2M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $0 | -$7.2M | — |
| Dec 31, 2025 | $12.6M | $31.5M | 250.7% |
| Sep 30, 2025 | $0 | -$7.4M | — |
| Jun 30, 2025 | $0 | -$1.7M | — |
From Spero Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…